Recommended Tools
AbSeek™ encompasses antibody sequence analysis, structure and function prediction, lead optimization, de novo generation, and visualization, among others, covering all stages of antibody discovery and engineering from screening to optimization for efficient innovation.
Free Tools Limited Time
Sequence Analysis
Function Prediction
Lead Optimization
Structure Prediction
New
Molecule Generation

Features & Advantages
Integration
Combines multiple algorithms to provide a one-stop service that meets all needs in antibody discovery and engineering.
Expertise
Tailors UI and data visualization methods based on the characteristics of antibody data for better suitability.
Advancement
Continuously updates cutting-edge AI algorithms to ensure the platform's timeliness and advancement.
Data Security
Committed to providing users with a secure and reliable data environment, alleviating concerns about data leakage.
News
Cyagen Talk|AI-Powered Antibody Discovery: From HUGO-Ab Mice to Predictive Models
AbSeek™: Intelligent Antibody Computational Platform
2025-03-19
More >>【Frontier Express】Signal Transduction and Targeted Therapy | Bispecific Antibody Study Targeting the IL-17/IL-36 Pathogenic Hub in Hidradenitis Suppurativa
2026-10-20
【Frontier Express】Signal Transduction and Targeted Therapy | A Randomized Phase II Trial of Camrelizumab-Induced Concurrent Chemoradiotherapy and Consolidation Therapy for Limited-Stage Small Cell Lung Cancer
2026-10-20
【Frontier Express】Nature Medicine | Phase 3 Randomized Controlled Trial of Obinutuzumab β in Anti-Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder
2026-10-20
【Frontier Express】Nature | A Binding-to-Release Strategy for Targeted Anticancer Drug Delivery
2026-10-20
【Frontier Express】Cancer Cell | Tumor-Infiltrating Plasma Cells Target Citrullinated Proteins to Reveal New Targets for Immunotherapy
2026-10-20
【Frontier Express】Journal of Hematology & Oncology | 2026 ASCO Update: Frontier Advances in Antibody-Based Regimens for Large B-Cell Lymphoma
2026-10-20
【Frontier Express】Nature Medicine | Phase 3 Randomized Controlled Trial of Obinutuzumab β for Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder
2026-10-19






